Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation (2016)

Viridian Therapeutics, Inc.\DE has reported Accumulated Depreciation over the past 3 years, most recently at $881000.0 for Q3 2016.

  • Quarterly results put Accumulated Depreciation at $881000.0 for Q3 2016, up 27.31% from a year ago — trailing twelve months through Sep 2016 was $881000.0 (up 27.31% YoY), and the annual figure for FY2015 was $739000.0, up 33.15%.
  • Accumulated Depreciation for Q3 2016 was $881000.0 at Viridian Therapeutics, Inc.\DE, up from $834000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation for VRDN hit a ceiling of $881000.0 in Q3 2016 and a floor of $483342.0 in Q2 2014.
  • Median Accumulated Depreciation over the past 3 years was $668500.0 (2015), compared with a mean of $673280.8.
  • Biggest five-year swings in Accumulated Depreciation: skyrocketed 33.73% in 2015 and later rose 27.31% in 2016.
  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation stood at $555000.0 in 2014, then soared by 33.15% to $739000.0 in 2015, then grew by 19.22% to $881000.0 in 2016.
  • The last three reported values for Accumulated Depreciation were $881000.0 (Q3 2016), $834000.0 (Q2 2016), and $786000.0 (Q1 2016) per Business Quant data.